Cogstate (ASX:CGS) Receivables Turnover: 1.98 (As of Dec. 2025)


ASX:CGS Cogstate Ltd ASX:CGS
77 GF Score
Price A$2.74
GF Value A$2.10
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cogstate Receivables Turnover?

Cogstate ASX:CGS +1.11% 77 Receivables Turnover is 1.98 as of Dec. 2025. GuruFocus rates ASX:CGS with a GF Score™ of 77/100 and a GF Value™ of A$2.10 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 657 Healthcare Providers & Services companies, Cogstate ranks worse than 76.41% on this metric.

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cogstate's Revenue for the six months ended in Dec. 2025 was A$38.80 Mil. Cogstate's average Accounts Receivable for the six months ended in Dec. 2025 was A$19.57 Mil. Hence, Cogstate's Receivables Turnover for the six months ended in Dec. 2025 was 1.98.


Cogstate  (ASX:CGS) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.


Cogstate Receivables Turnover Related Terms


Cogstate Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Cogstate's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogstate Receivables Turnover Chart

Cogstate Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.16 5.87 5.27 4.92 4.47

Cogstate Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.34 2.73 2.35 2.40 1.98

ASX:CGS vs VEEV, BTSG, TEM: Receivables Turnover Comparison

For the Health Information Services subindustry, Cogstate's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cogstate Receivables Turnover vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cogstate's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Cogstate's Receivables Turnover falls into.


ASX:CGS
77GF Score
Cogstate Ltd ASX:CGS
Receivables Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogstate Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Cogstate's Receivables Turnover for the fiscal year that ended in Jun. 2025 is calculated as

Receivables Turnover (A: Jun. 2025 )
=Revenue / Average Accounts Receivable
=Revenue (A: Jun. 2025 ) / ((Accounts Receivable (A: Jun. 2024 ) + Accounts Receivable (A: Jun. 2025 )) / count )
=78.049 / ((15.218 + 19.67) / 2 )
=78.049 / 17.444
=4.47

Cogstate's Receivables Turnover for the quarter that ended in Dec. 2025 is calculated as

Receivables Turnover (Q: Dec. 2025 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Dec. 2025 ) / ((Accounts Receivable (Q: Jun. 2025 ) + Accounts Receivable (Q: Dec. 2025 )) / count )
=38.799 / ((19.67 + 19.475) / 2 )
=38.799 / 19.5725
=1.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Receivables Turnover →
What does a Receivables Turnover of 1.98 mean?
Cogstate (ASX:CGS) has a Receivables Turnover of 1.98 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cogstate and its competitors. According to the industry distribution chart, Cogstate ranks #502 out of 657 companies in the Healthcare Providers & Services industry, placing it in the top 76.4%.
Is Cogstate's Receivables Turnover too high?
Cogstate's current Receivables Turnover is 1.98. The Healthcare Providers & Services industry median Receivables Turnover is 7.68. Cogstate's value of 1.98 is 74.2% below this industry median. Based on the distribution chart, Cogstate ranks #502 out of 657 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cogstate has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's Receivables Turnover compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cogstate ranks #502 out of 657 companies for Receivables Turnover. This places Cogstate in the lower half of its industry. The industry median Receivables Turnover is 7.68. Cogstate's value of 1.98 is 74.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.68, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogstate's current Receivables Turnover of 1.98 is 74.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cogstate and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogstate's current Receivables Turnover is 1.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (ASX:CGS) is currently considered Modestly Overvalued. The stock's GF Value™ is A$2.10, compared to a current price of A$2.74 — trading 30.5% above its estimated fair value. The current Receivables Turnover is 1.98 and 74.2% below the Healthcare Providers & Services industry median of 7.68. Cogstate's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Cogstate (ASX:CGS), the current Receivables Turnover is 1.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cogstate (ASX:CGS) Overvalued in 2026?

Based on GuruFocus' analysis, Cogstate stock appears to be overvalued. The current stock price of A$2.74 is trading 30.5% above its estimated GF Value™ of A$2.10. GuruFocus considers Cogstate to be Modestly Overvalued.

Key valuation signals for ASX:CGS:

  • Receivables Turnover: 1.98
  • GF Value™: A$2.10 vs. price of A$2.74 (30.5% above fair value)
  • GF Score™: 77/100 with 4 warning signs
  • Industry Position: 74.2% below the Healthcare Providers & Services median (#502 of 657)

No single metric tells the full story. See the ASX:CGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cogstate Business Description

Other Exchanges COGZF:USAC4B:Germany
Address 367 Collins Street, Level 32, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
77GF Score

Get the complete analysis for ASX:CGS

Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.74
Price
A$2.10
GF Value